nCounter® Metabolic Pathways Panel
Helping Your Research
Quantify the expression of hundreds of genes involved in core metabolic processes and immunometabolism for human or mouse samples in a reliable, simple, and robust way using the nCounter Metabolic Pathways Panel. Understand the complex mechanisms behind metabolic adaptation, metabolic switching, metabolic alterations, and study changes in mitochondrial respiration and glycolysis.
The Metabolic Pathways Panel helps advance efforts towards novel therapeutic targets that take advantage of altered metabolism in cancer and other diseases. Get results in less than 24 hours from multiple sample types with a workflow that maximizes insight and minimizes turnaround time:
- Quantify the presence and relative abundance of 14 different immune cell types for immunometabolism studies
- Bypass RT and amplification by direct detection, yielding highly reproducible data
- Process your samples with < 30 minutes hands-on time and get results in < 24 hours
- Receive publication-ready figures with off-the-shelf data analysis with nSolver™ Data Analysis Software
How It Works
The underlying molecular mechanisms behind alterations in metabolic pathways, signaling pathways, and cell stress can now be fully elucidated, giving you a complementary tool to traditional metabolite assays for profiling metabolic checkpoints and potential therapeutic targets.
Directly profile 768 genes in human or mouse across 34 annotated pathways involved in five important themes for metabolism research:
Biosynthesis and Anabolic Pathways
Nutrient Capture and Catabolic Pathways
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.
The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.
Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.
Local recurrences in early gastric cancers (EGCs) after complete endoscopic submucosal dissection (ESD) remain problematic. Here, we investigated the spatially sequential molecular changes in various cancer-related proteins along the axis of the histologically clear but recurrent resection margins (TRM) to determine the appropriate tumor-free margin distance and potential molecular risk markers related to local recurrence.
PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.
Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role.